Franklin Genomic Advancements ETF (HELX) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores HELX 4.2 out of 10 — highest on Growth (9.7), lowest on Quality (0.2). It trades at 29.5 times earnings, against its own median of 30.0. Its ten largest holdings are 50% of the fund.
What stands out in HELX's data
A focused genomic-advancement strategy, owning health and biotech stocks.
Its profitability trails most peers — the fund's edge has to come from its growth story, not its current earnings.
EBITDA margin of 16.9% trails the category median of 20.5% and its own 19.0% historical median, though analysts see 42% growth ahead.
A targeted bet on genomic medicine, separate from a core health-care allocation.
Why did HELX move this week? It fell 2.6% in the week to October 9, 2026 — Twist Bioscience and Guardant Health drove it
HELX fell 2.6% in the week to October 9, 2026. The holdings that moved it most were Twist Bioscience (−15.3%), Guardant Health (−5.8%) and Adaptive Biotechnologies (−6.6%); Krystal Biotech (+2.9%) pushed the other way.
How is HELX rated? ETF Copilot scores Franklin Genomic Advancements ETF (HELX) 4.2 out of 10
As of October 9, 2026, ETF Copilot scores Franklin Genomic Advancements ETF (HELX) 4.2 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 4.2 / 10
- Growth: 9.7 / 10
- Value: 4.9 / 10
- Risk: 1.5 / 10
- Quality: 0.2 / 10
- Return: 2.6 / 10
Is HELX expensive right now? It trades at 29.5 times earnings, against its own median of 30.0
As of October 9, 2026, HELX is cheaper than 53% of its own last 5 years.
Trailing 12 months, built from HELX's holdings. How we calculate this →
What's inside HELX?
What's inside HELX: Size (Large 28%, Mid 57%, Small 15%); Geography (International 10%, US 90%); Tech 0.8%; AI 3.5%.
What are HELX's top holdings? The ten largest are 50% of the fund
Natera, Guardant Health, Krystal Biotech, Adaptive Biotechnologies, Twist Bioscience, Ligand Pharmaceuticals, Bridgebio Pharma, Medpace, Vertex Pharmaceuticals and United Therapeutics are HELX's largest holdings, in that order.
More concentrated than 54% of Health & Biotech ETFs.
Half of HELX's weight sits in its 11 largest positions, and once those weights are taken into account it behaves like 26 equally weighted holdings.
What is HELX's expense ratio? 0.50% a year
As of October 9, 2026, HELX charges 0.50% a year, yields 0.35% and holds $29M in assets across 68 positions.
| Measure | HELX |
|---|---|
| Expense ratio | 0.50% |
| Dividend yield | 0.35% |
| Assets under management | $29M |
| Holdings | 68 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “Franklin Genomic Advancements ETF (HELX) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/helx
ETF Copilot Pro unlocks HELX's price and what each holding weighs.
Try Pro free →